Tian et al[16] indicated that bellidifolin likely possessed a hypoglycemic activity by reducing hepatic glucose output through increasing the G6Pase activity and decreasing the glucokinase activity, showing a high potential for hypoglycemic and hypolipidemic treatment in type-2 diabetes. This evidence concerns the gene G6PC1 and type 2 diabetes mellitus.